Journal
CURRENT MEDICAL RESEARCH AND OPINION
Volume 33, Issue 11, Pages 2049-2056Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/03007995.2017.1354826
Keywords
Daily teriparatide; osteoporosis; clinical fractures; observational study; Japan
Funding
- Eli Lilly Japan K.K.
Ask authors/readers for more resources
Objective: The Japan Fracture Observational Study (JFOS), a prospective observational study, investigated the real-world effectiveness of daily teriparatide to reduce clinical fracture risk in osteoporotic patients.Methods: In routine clinical practice, Japanese patients initiated on teriparatide 20g/day by subcutaneous injection were enrolled. The primary end-point was the rate of clinical fractures at 6-month intervals over 24 months. Bone mineral density (BMD), procollagen type 1 aminoterminal propeptide (P1NP), back pain, and health-related quality-of-life (HRQoL) information was collected.Results: Of 1,996 patients at baseline, 90.1% were female, and mean age was 76.9 years. Teriparatide persistence at 12 and 24 months was 68.0% and 51.6%, respectively. Compared to the first 6-month treatment interval, the odds ratio of fractures decreased by 56.4% during 6-12 months, 51.6% during 12-18 months, and 58.8% during 18-24 months (all p<.01). After 24 months, BMD increased by 17.2% (lumbar spine) and 7.9% (total hip). After 6 months, P1NP levels increased by 259.3%. A reduction in back pain (100mm visual analog scale) of 16.1mm at 3 months was maintained through 24 months. HRQoL (pain, daily living activities, general health) improved by 10% at each post-baseline time point. Of 279 (14.6%) patients with 1 adverse event (AE), 71 (3.7%) experienced 1 drug-related AE (investigator assessed), including nausea (0.7%), dizziness (0.4%), and decreased appetite (0.3%). Osteosarcoma was not reported; there were no new safety signals.Conclusions: JFOS demonstrated effectiveness of teriparatide 20g/day to reduce the risk of clinical fractures in Japanese patients in a real-world setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available